HPVs representing the most common sexually transmitted disease are a group of carcinogenic viruses with different oncogenic potential. The immune system and the vaginal microbiome represent the modifiable and important risk factors in HPV-induced carcinogenesis. HPV infection significantly increases vaginal microbiome diversity, leading to gradual increases in the abundance of anaerobic bacteria and consequently the severity of cervical dysplasia. Delineation of the exact composition of the vaginal microbiome and immune environment before HPV acquisition, during persistent/progressive infections and after clearance, provides insights into the complex mechanisms of cervical carcinogenesis. It gives hints regarding the prediction of malignant potential. Relative high HPV prevalence in the general population is a challenge for modern and personalized diagnostics and therapeutic guidelines. Identifying the dominant microbial biomarkers of high-grade and low-grade dysplasia could help us to triage the patients with marked chances of lesion regression or progression. Any unnecessary surgical treatment of cervical dysplasia could negatively affect obstetrical outcomes and sexual life. Therefore, understanding the effect and role of microbiome-based therapies is a breaking point in the conservative management of HPV-associated precanceroses. The detailed evaluation of HPV capabilities to evade immune mechanisms from various biofluids (vaginal swabs, cervicovaginal lavage/secretions, or blood) could promote the identification of new immunological targets for novel individualized diagnostics and therapy. Qualitative and quantitative assessment of local immune and microbial environment and associated risk factors constitutes the critical background for preventive, predictive, and personalized medicine that is essential for improving state-of-the-art medical care in patients with cervical precanceroses and cervical cancer. The review article focuses on the influence and potential diagnostic and therapeutic applications of the local innate immune system and the microbial markers in HPV-related cancers in the context of 3P medicine.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8192654PMC
http://dx.doi.org/10.1007/s13167-021-00244-3DOI Listing

Publication Analysis

Top Keywords

vaginal microbiome
16
cervical cancer
8
immune system
8
risk factors
8
cervical dysplasia
8
cervical
6
immune
5
interplay vaginal
4
microbiome
4
microbiome innate
4

Similar Publications

Vulvovaginal candidiasis (VVC), a condition predominantly caused by , affects millions of women worldwide, prompting the need for alternative treatments due to the side effects and increasing resistance associated with conventional imidazole antifungals. This study investigated VAGINNE, a novel fermentation broth derived from species, as a potential VVC treatment. Using a BALB/c mouse model of infection, we evaluated VAGINNE's effects on vaginal microbiome composition, inflammatory markers, and tissue integrity.

View Article and Find Full Text PDF

An Overview of Early-Life Gut Microbiota Modulation Strategies.

Ann Nutr Metab

January 2025

Department of Paediatrics, Medical University of Warsaw, Warsaw, Poland.

Background: The gut microbiota, or microbiome, is essential for human health. Early-life factors such as delivery mode, diet, and antibiotic use shape its composition, impacting both short- and long-term health outcomes. Dysbiosis, or alterations in the gut microbiota, is linked to conditions such as allergies, asthma, obesity, diabetes, inflammatory bowel disease, and necrotizing enterocolitis in preterm infants.

View Article and Find Full Text PDF

Lactic acid in the vaginal milieu modulates the -host interaction.

Virulence

December 2025

Department of Internal Medicine and Radboud Center for Infectious Diseases, Radboud University Medical Center, Nijmegen, T he Netherlands.

Vulvovaginal candidiasis (VVC) is one of the most common infections caused by . VVC is characterized by an inadequate hyperinflammatory response and clinical symptoms associated with colonization of the vaginal mucosa. Compared to other host niches in which can cause infection, the vaginal environment is extremely rich in lactic acid that is produced by the vaginal microbiota.

View Article and Find Full Text PDF

TSST-1 promotes colonization of within the vaginal tract by activation of CD8 T cells.

Infect Immun

January 2025

Department of Microbiology and Immunology, Schulich School of Medicine and Dentistry, University of Western Ontario, London, Ontario, Canada.

Toxic shock syndrome toxin-1 (TSST-1) is a superantigen produced by and is the determinant of menstrual toxic shock syndrome (mTSS); however, the impact of TSST-1 on the vaginal environment beyond mTSS is not understood. Herein, we assessed how TSST-1 affects vaginal colonization by , host inflammatory responses, and changes in microbial communities within the murine vagina. We demonstrated that TSST-1 induced a CD8 T-cell-dependent inflammatory response in 24 h that correlated with persistence within the vaginal tract.

View Article and Find Full Text PDF

Background: A dysbiotic vaginal microbiome (VMB) is associated with clinical conditions such as bacterial vaginosis (BV) and an increased risk of human immunodeficiency virus (HIV-1) infection. Considering the high prevalence of BV among African, Caribbean and Black (ACB) women, we conducted a prospective, randomized, open-label phase 1 clinical trial to determine the feasibility, safety and tolerability of administering low-dose estrogen, probiotics or both in combination to improve vaginal health and decrease HIV-1 susceptibility.

Methods: ACB women aged 18-49 from the Greater Toronto Area (GTA) were randomized to one of four study arms: intravaginal estradiol (Estring©; 7.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!